key: cord-0772238-sapj5758
authors: Prado-Vivar, Belén; Becerra-Wong, Mónica; Guadalupe, Juan José; Márquez, Sully; Gutierrez, Bernardo; Rojas-Silva, Patricio; Grunauer, Michelle; Trueba, Gabriel; Barragán, Verónica; Cárdenas, Paúl
title: A case of SARS-CoV-2 reinfection in Ecuador
date: 2020-11-23
journal: Lancet Infect Dis
DOI: 10.1016/s1473-3099(20)30910-5
sha: 5927dae272ebb28bebb1440d7c57b3ad6b5cddc2
doc_id: 772238
cord_uid: sapj5758

nan

Cases of severe acute respiratory syn drome coronavirus 2 (SARSCoV2) reinfection have been reported in Hong Kong, Belgium, the Netherlands, and the USA. [1] [2] [3] [4] Here we report the first confirmed case of SARSCoV2 reinfection in Ecuador and South America. For full methodological details, see the appendix (pp 1, 2). On May 12, 2020, a 46yearold man presented in Quito, Ecuador, with 3 days of intense headache and drowsiness. On May 16, he took a rapid antibody test that was positive for IgM and negative for IgG. On May 20, the patient tested positive on RTPCR (ORF3a gene, Cq=36·85). Subsequently, the patient's symptoms improved, and he tested negative on RTPCR on June 3 (appendix p 4).

On July 20, the patient presented once again with symptoms suggestive of COVID19. This time the symptoms were more severe and included odynophagia, nasal congestion, fever of 38·5°C, back pain, productive cough, and dyspnoea. He received an RTPCR test on July 22, with a positive result (N gene, Cq=30·82). Despite having moderate symptoms and dyspnoea, the patient did not require hospitalisation, and his clinical status improved after several days. A fourth RTPCR test was done on Aug 4, which was negative (appendix p 4). Finally, an ELISA quantitative antibody test was done on Aug 18, showing anti SARSCoV2 IgG (34·1 NovaTec Units [NTU]) and IgM (54·2 NTU; both interpreted as positive).

SARSCoV2 genome sequencing was done using Oxford Nanopore Technologies' MinION, following the ARTIC Network protocols. 5 Phylogenetic analysis revealed that the first infection variant belonged to clade 20A and lineage B1.p9, whereas the second infection variant belonged to clade 19B and lineage A.1.1 (appendix p 4). The mutation loci and amino acid changes are described in the appendix (p 5). No shared mutations were observed between the two sequences, further suggesting that both variants resulted from distinct evolutionary trajectories.

Although reinfections with corona viruses that cause the common cold have been reported previously, 6 the symptoms of reinfections are usually milder than those of the primary infections. It was therefore surprising that our patient showed more severe disease with the second infection than with the first, especially because the patient did not have any additional clinical conditions that could explain it. Increased severity of second SARSCoV2 infections has been reported previously: in a healthy man aged 25 years in Nevada, USA, 2 and in an immunocompromised woman aged 89 years in the Netherlands, which resulted in her death. 4 The protective immune response to SARSCoV2 infection is not fully understood; however, protection against severe disease has been shown in animal models and inferred in humans infected with the virus. 7 Interestingly, the antibody test performed during the first infection event showed the presence of specific antiSARSCoV2 IgM and no IgG. However, it is not possible using conventional antibody tests to determine whether a protective immune response developed. BPV 

Colegio de Ciencias Biológicas y Ambientales, and Centro de Bioinformática (BPV, PC) and Escuela de Medicina (MG)

COVID19 reinfection by a phylogenetically distinct SARScoronavirus2 strain confirmed by whole genome sequencing

Genomic evidence for reinfection with SARSCoV2: a case study

What reinfections mean for COVID19

Reinfection of SARSCoV2 in an immunocompromised patient: a case report

Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples

The time course of the immune response to experimental coronavirus infection of man

High prevalence of SARSCoV2 antibodies in care homes affected by COVID19: prospective cohort study

See Online for appendix Lancet Infect Dis